IBJNews

Lilly shares get boost from OK of rival's drug

Back to TopCommentsE-mailPrintBookmark and Share

Shares of Eli Lilly and Co. and its partner Amylin Pharmaceuticals Inc. rose in pre-market trading on hopes that the companies’ new version of diabetes treatment Byetta will be approved following U.S. regulators’ clearance of a similar drug.

The U.S. Food and Drug Administration on Monday approved Victoza, a drug developed by Denmark-based Novo Nordisk A/S to compete against Byetta. Victoza is a once-daily shot, compared with the twice-daily Byetta.

But Indianapolis-based Lilly and San Diego-based Amylin have asked the FDA to approve a once-weekly version of Byetta, which would be the most convenient for patients. Analysts expect sales of once-weekly Byetta to reach as high as $2 billion by 2015, which would be split by Lilly and Amylin. Sales of twice-daily Byetta last year were on pace to reach about $790 million.

What’s been holding up Victoza and the once-weekly Byetta have been regulator concerns about patients developing inflammation of the pancreas while taking the drugs.

In approving Victoza, the FDA required its label to carry a warning about pancreatitis as well as a prohibition against use in patients at risk for a rare thyroid cancer after tumors developed in rodents.

Those warnings were milder than many analysts had feared.

“Given the fact that the FDA has clearly been agonizing over whether to approve this or not, it isn’t bad,” said Jack Scannell, an analyst at Sanford C. Bernstein Ltd. in London, who estimates Victoza could generate $900 million in annual sales by 2015.

Other analysts’ said the FDA’s decision on Victoza makes it likelier to approve once-weekly Byetta under the same terms.

“We continue to believe that Byetta LAR will receive the same treatment from the FDA” as Victoza, wrote analyst Joshua Schimmer of Leerink Swann, in a note to clients today.

Yaron Werber of Citigroup, wrote in a report to clients today, that the FDA is due to make a decision on once-weekly Byetta by March 5.

In morning trading, Amylin and Novo both saw their stock prices jump. Amylin shares rose as high as 14.5 percent and Novo shares surged as much as 4 percent. Lilly's stock price rose as much as 1 percent, to $36.14.

ADVERTISEMENT

Post a comment to this story

COMMENTS POLICY
We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
 
You are legally responsible for what you post and your anonymity is not guaranteed.
 
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
 
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
 
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.
 

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. By Mr. Lee's own admission, he basically ran pro-bono ads on the billboard. Paying advertisers didn't want ads on a controversial, ugly billboard that turned off customers. At least one of Mr. Lee's free advertisers dropped out early because they found that Mr. Lee's advertising was having negative impact. So Mr. Lee is disingenous to say the city now owes him for lost revenue. Mr. Lee quickly realized his monstrosity had a dim future and is trying to get the city to bail him out. And that's why the billboard came down so quickly.

  2. Merchants Square is back. The small strip center to the south of 116th is 100% leased, McAlister’s is doing well in the outlot building. The former O’Charleys is leased but is going through permitting with the State and the town of Carmel. Mac Grill is closing all of their Indy locations (not just Merchants) and this will allow for a new restaurant concept to backfill both of their locations. As for the north side of 116th a new dinner movie theater and brewery is under construction to fill most of the vacancy left by Hobby Lobby and Old Navy.

  3. Yes it does have an ethics commission which enforce the law which prohibits 12 specific items. google it

  4. Thanks for reading and replying. If you want to see the differentiation for research, speaking and consulting, check out the spreadsheet I linked to at the bottom of the post; it is broken out exactly that way. I can only include so much detail in a blog post before it becomes something other than a blog post.

  5. 1. There is no allegation of corruption, Marty, to imply otherwise if false. 2. Is the "State Rule" a law? I suspect not. 3. Is Mr. Woodruff obligated via an employment agreement (contractual obligation) to not work with the engineering firm? 4. In many states a right to earn a living will trump non-competes and other contractual obligations, does Mr. Woodruff's personal right to earn a living trump any contractual obligations that might or might not be out there. 5. Lawyers in state government routinely go work for law firms they were formally working with in their regulatory actions. You can see a steady stream to firms like B&D from state government. It would be interesting for IBJ to do a review of current lawyers and find out how their past decisions affected the law firms clients. Since there is a buffer between regulated company and the regulator working for a law firm technically is not in violation of ethics but you have to wonder if decisions were made in favor of certain firms and quid pro quo jobs resulted. Start with the DOI in this review. Very interesting.

ADVERTISEMENT